GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Ra Pharmaceuticals Inc (NAS:RARX) » Definitions » Price-to-Free-Cash-Flow

Ra Pharmaceuticals (Ra Pharmaceuticals) Price-to-Free-Cash-Flow : N/A (As of Apr. 25, 2024)


View and export this data going back to 2016. Start your Free Trial

What is Ra Pharmaceuticals Price-to-Free-Cash-Flow?

As of today (2024-04-25), Ra Pharmaceuticals's share price is $47.99. Ra Pharmaceuticals's Free Cash Flow per Share for the trailing twelve months (TTM) ended in Dec. 2019 was $-1.98. Hence, Ra Pharmaceuticals's Price-to-Free-Cash-Flow Ratio for today is N/A.

The historical rank and industry rank for Ra Pharmaceuticals's Price-to-Free-Cash-Flow or its related term are showing as below:

RARX's Price-to-Free-Cash-Flow is not ranked *
in the Biotechnology industry.
Industry Median: 31.19
* Ranked among companies with meaningful Price-to-Free-Cash-Flow only.

Ra Pharmaceuticals's Free Cash Flow per Share for the three months ended in Dec. 2019 was $-0.61. Its Free Cash Flow per Share for the trailing twelve months (TTM) ended in was $-1.98.


Ra Pharmaceuticals Price-to-Free-Cash-Flow Historical Data

The historical data trend for Ra Pharmaceuticals's Price-to-Free-Cash-Flow can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Ra Pharmaceuticals Price-to-Free-Cash-Flow Chart

Ra Pharmaceuticals Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19
Price-to-Free-Cash-Flow
Get a 7-Day Free Trial - - - - -

Ra Pharmaceuticals Quarterly Data
Dec14 Sep15 Dec15 Mar16 Jun16 Sep16 Dec16 Mar17 Jun17 Sep17 Dec17 Mar18 Jun18 Sep18 Dec18 Mar19 Jun19 Sep19 Dec19
Price-to-Free-Cash-Flow Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only - - - - -

Competitive Comparison of Ra Pharmaceuticals's Price-to-Free-Cash-Flow

For the Biotechnology subindustry, Ra Pharmaceuticals's Price-to-Free-Cash-Flow, along with its competitors' market caps and Price-to-Free-Cash-Flow data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Ra Pharmaceuticals's Price-to-Free-Cash-Flow Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Ra Pharmaceuticals's Price-to-Free-Cash-Flow distribution charts can be found below:

* The bar in red indicates where Ra Pharmaceuticals's Price-to-Free-Cash-Flow falls into.



Ra Pharmaceuticals Price-to-Free-Cash-Flow Calculation

Ra Pharmaceuticals's Price-to-Free-Cash-Flow ratio for today is calculated as

Price-to-Free-Cash-Flow Ratio=Share Price/ Free Cash Flow per Share (TTM)
=47.99/-1.975
=N/A

Ra Pharmaceuticals's Share Price of today is $47.99.
Ra Pharmaceuticals's Free Cash Flow per Share for the trailing twelve months (TTM) ended in Dec. 2019 adds up the quarterly data reported by the company within the most recent 12 months, which was $-1.98.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

It can also be calculated from the numbers for the whole company:

Price-to-Free-Cash-Flow Ratio=Market Cap/Free Cash Flow

Ra Pharmaceuticals  (NAS:RARX) Price-to-Free-Cash-Flow Explanation

Free Cash Flow is considered more important than earnings by value investors. The reason is because, in principle, only the net cash that can be taken from the business belongs to shareholders. This Free Cash Flow can be used to grow the business, reduce debt or return to shareholders in dividends or share buybacks.

In a DCF Calculation Free Cash Flow is used to determine the intrinsic value of companies.


Be Aware

In real business, Free Cash Flow can be affected by the change in accounts receivable, accounts payable, management's decision on expansion, etc. Therefore, investors should look at the Free Cash Flow over the longer term. Long-term average of Free Cash Flow is a more reliable indicator for real free cash flow.


Ra Pharmaceuticals Price-to-Free-Cash-Flow Related Terms

Thank you for viewing the detailed overview of Ra Pharmaceuticals's Price-to-Free-Cash-Flow provided by GuruFocus.com. Please click on the following links to see related term pages.


Ra Pharmaceuticals (Ra Pharmaceuticals) Business Description

Traded in Other Exchanges
N/A
Address
87 Cambridge Park Drive, Cambridge, MA, USA, 02140
Ra Pharmaceuticals Inc is a clinical-stage biopharmaceutical company. It discovers and develops therapeutics for the treatment of diseases caused by excessive or uncontrolled activation of the complement system. Geographically business of the firm can be seen amplifying in the United States, Europe and even at international level.
Executives
Peter Kolchinsky director, 10 percent owner 200 BERKELEY STREET, 18TH FLOOR, BOSTON MA 02116
Edward T Mathers director C/O MEDIMMUNE, INC., ONE MEDIMMUNE WAY, GAITHERSBURG MD 20878
Timothy R Pearson director C/O TESARO, INC., 1000 WINTER STREET, SUITE 3300, WALTHAM MA 02451
Aoife Brennan director 200 SIDNEY STREET, SUITE 320, C/O SYNLOGIC, INC., CAMBRIDGE MA 02139
Douglas A Treco director, officer: President and CEO 87 CAMBRIDGEPARK DRIVE, C/O RA PHARMACEUTICALS, INC., CAMBRIDGE MA 02140
Nea Partners 13, Limited Partnership 10 percent owner 1119 ST. PAUL STREET, BALTIMORE MD 21202
Nea 13 Gp, Ltd 10 percent owner 1119 ST. PAUL STREET, BALTIMORE MD 21202
New Enterprise Associates 13 Lp 10 percent owner 1119 ST PAUL STREET, BALTIMORE MD 21202
Rajeev M. Shah director, 10 percent owner 200 BERKELEY STREET, 18TH FLOOR, BOSTON MA 02116
Alexander Cumbo director 215 FIRST STREET, SUITE 415, CAMBRIDGE MA 02142
Robert Heft director 87 CAMBRIDGEPARK DRIVE, C/O RA PHARMACEUTICALS, INC., CAMBRIDGE MA 02140
Patrick J Kerins 10 percent owner
Ra Capital Management, L.p. director, 10 percent owner 200 BERKELEY STREET, 18TH FLOOR, BOSTON MA 02116
Ra Capital Healthcare Fund Lp director, 10 percent owner 200 BERKELEY STREET, 18TH FLOOR, BOSTON MA 02116
David Charles Lubner officer: Executive VP and CFO C/O TETRAPHASE PHARMACEUTICALS, INC., 480 ARSENAL STREET, SUITE 110, WATERTOWN MA 02472

Ra Pharmaceuticals (Ra Pharmaceuticals) Headlines

From GuruFocus

4 Stocks With More Than 20% Price Increases on Thursday

By James Li James Li 10-10-2019